Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Active not recruiting 10Recruiting 7Completed 2Terminated 1Suspended 1Not yet recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 1

Conditions

Breast Neoplasms 217Neoplasms 196Carcinoma, Non-Small-Cell Lung 94Colorectal Neoplasms 92Prostatic Neoplasms 79Lung Neoplasms 74Multiple Myeloma 49Head and Neck Neoplasms 48Neoplasm Metastasis 46Melanoma 46Pancreatic Neoplasms 44Leukemia, Myeloid, Acute 41Carcinoma, Hepatocellular 41Recurrence 35Brain Neoplasms 35Squamous Cell Carcinoma of Head and Neck 34Ovarian Neoplasms 32Glioblastoma 30Uterine Cervical Neoplasms 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Sarcoma 27Glioma 27Lymphoma, Non-Hodgkin 26Lymphoma 26Stomach Neoplasms 25Carcinoma, Renal Cell 25Lymphoma, Follicular 24Colonic Neoplasms 24Motor Activity 22Esophageal Neoplasms 22

Interventions

Nivolumab 2Ipilimumab 2Temozolomide 1Radiotherapy 1Radiation 1Magnetic Resonance Spectroscopy 1Contrast Media 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Gliosarcoma × 90 days × Clear all
NCT04396860 2026-04-22

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

National Cancer Institute (NCI)

Phase 2/3 Completed
159 enrolled 17 charts
Sarcoma

Gliosarcoma

NCT04817254 2026-04-17

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
47 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡